Antitumor Effects of Immunotherapy with Xenogeneic VEGF Vaccine Combined with Chemotherapy on Solid Tumor in Mice
NIU Ting,LIU Ting,JIA Yong-qian,LIU Ji-yan,WU Yang,HU Bing,TIAN Ling,YANG Li,KAN Bing,WEI Yu-Quan
DOI: https://doi.org/10.3969/j.issn.1000-8861.2005.05.001
2005-01-01
Abstract:Objective To explore antitumor effects of immunotherapy with recombinant Xenopus laevis vascular endothelial growth factor (xVEGF) as a vaccine combined with low-dose adriamycin in Meth A fibrosarcoma model in mice. Methods Mice were randomized into four groups: combination therapy, adriamycin alone, xVEGF alone, and normal saline (NS) groups. Tumor growth, survival rate of tumor-bearing mice, and potential toxicity of regimens above were observed. Anti-VEGF antibodies and anti-VEGF antibody-producing B cells (APBCs) were detected by Western blot analysis and enzyme-linked immunospot (ELISPOT) assay, respectively. In addition, microvessel density (MVD) of tumor and tumor cell apoptosis were detected by immunohistochemistry and TUNEL staining, respectively. Results Tumor volumes of mice in combination group were significantly smaller than those in adriamycin alone group, in xVEGF alone group (P 0.05), or in NS group (P 0.01). Complete regression of tumor was observed in 3 of 10 mice in combination group. Forty-eight days after inoculation of tumor cells, survival rate of mice was significantly higher in combination group than that in adriamycin alone group, in xVEGF alone group (P 0.05), or in NS group (P 0.01). Anti-VEGF antibodies were found by Western blot analysis in mice treated with xVEGF (combination or xVEGF alone group), and anti-VEGF APBCs counts in these two groups were significantly higher compared with adriamycin alone or NS group (P 0.01). Significant difference was found between combination group and other three groups in terms of MVD in tumor tissues and tumor cell apoptosis (P 0.05). Conclusion The combination therapy of xVEGF and low-dose adriamycin induces synergistic antitumor effect on solid tumor in mice.